Alumis Inc. (NASDAQ:ALMS - Get Free Report)'s stock price gapped up before the market opened on Thursday . The stock had previously closed at $11.19, but opened at $11.63. Alumis shares last traded at $11.23, with a volume of 9,568 shares traded.
Wall Street Analysts Forecast Growth
ALMS has been the subject of several research reports. Leerink Partnrs raised Alumis to a "strong-buy" rating in a research note on Tuesday, July 23rd. Leerink Partners started coverage on Alumis in a research report on Tuesday, July 23rd. They issued an "outperform" rating and a $29.00 price objective for the company. Guggenheim started coverage on shares of Alumis in a research report on Tuesday, July 23rd. They set a "buy" rating and a $32.00 target price on the stock. HC Wainwright began coverage on shares of Alumis in a research note on Thursday. They issued a "buy" rating and a $30.00 target price on the stock. Finally, Morgan Stanley initiated coverage on shares of Alumis in a research note on Tuesday, July 23rd. They set an "overweight" rating and a $36.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $28.00.
Check Out Our Latest Research Report on Alumis
Alumis Stock Down 0.6 %
The business has a fifty day moving average price of $11.66.
Alumis (NASDAQ:ALMS - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($23.10) earnings per share for the quarter, missing the consensus estimate of ($1.57) by ($21.53). As a group, equities analysts forecast that Alumis Inc. will post -6.86 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SR One Capital Management LP acquired a new stake in Alumis during the 2nd quarter worth approximately $26,067,000. Yu Fan bought a new stake in shares of Alumis during the second quarter worth $10,502,000. Ally Bridge Group NY LLC acquired a new stake in shares of Alumis during the second quarter worth $8,229,000. Towerview LLC bought a new stake in Alumis in the 2nd quarter valued at $4,123,000. Finally, Millennium Management LLC acquired a new position in Alumis in the 2nd quarter worth $3,376,000.
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Read More
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
